01 3Mikeluna Combination Ophthalmic Solution
02 2Xalabrands
03 1Xalatan
04 6Xalatan/Xalacom
Main Therapeutic Indication : Ophthalmology
Currency : USD
2019 Revenue in Millions : 281
2018 Revenue in Millions : 318
Growth (%) : -12
Main Therapeutic Indication : Ophthalmology
Currency : USD
2021 Revenue in Millions : 44
2020 Revenue in Millions : 38
Growth (%) : 24
Main Therapeutic Indication : Ophthalmology
Currency : USD
2022 Revenue in Millions : 47
2021 Revenue in Millions : 44
Growth (%) : 7
Main Therapeutic Indication : Ophthalmology
Currency : USD
2022 Revenue in Millions : 195
2021 Revenue in Millions : 226
Growth (%) : -14
Main Therapeutic Indication : Ophthalmology
Currency : USD
2023 Revenue in Millions : 193
2022 Revenue in Millions : 195
Growth (%) : -1
Main Therapeutic Indication : Ophthalmology
Currency : USD
2023 Revenue in Millions : 46
2022 Revenue in Millions : 47
Growth (%) : 11
Main Therapeutic Indication : Opthamology
Currency : USD
2014 Revenue in Millions : -16.00%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Opthamology
Currency : USD
2015 Revenue in Millions : 495
2014 Revenue in Millions : 399
Growth (%) : -19%
Main Therapeutic Indication : Ophthalmology
Currency : USD
2016 Revenue in Millions : 363
2015 Revenue in Millions : 399
Growth (%) : -9
Main Therapeutic Indication : Ophthalmology
Currency : USD
2017 Revenue in Millions : 335
2016 Revenue in Millions : 362
Growth (%) : -7
LOOKING FOR A SUPPLIER?
